

# **Europe Colorectal Cancer Diagnostics Market - Industry Trends and Forecast to 2030**

Market Report | 2023-09-01 | 205 pages | Data Bridge Market Research

## **AVAILABLE LICENSES:**

- Single User License \$3500.00
- Corporate Users License \$4200.00

## Report description:

The Europe colorectal cancer diagnostics market is expected to reach USD 1,765.81 million by 2030 from USD 975.02 million in 2022, growing at a CAGR of 7.7% in the forecast period of 2023 to 2030.

Market Segmentation

Europe Colorectal Cancer Diagnostics Market, By Product Type (Instruments and Consumables & Accessories), Test Type (Stool Examination, Blood Test, Imaging Test, Tumor Markers, Biopsy and Others), Stages (Stage 0, Stage I, Stage II, Stage III and Stage IV), Cancer Type (Adenocarcinoma, Colorectal Lymphoma, Gastrointestinal Stromal Tumors, Carcinoid Tumors, and Others), Age Group (Geriatric, Adults and Pediatric), End User (Hospital, Diagnostic Centers, Cancer Research Centers, Ambulatory Surgical Centers, Academic Institutes, and Others), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Belgium, Switzerland, Rest of Europe) - Industry Trends and Forecast to 2030

Overview of Europe Colorectal Cancer Diagnostics Market Dynamics

Driver

- Growing prevalence of colorectal cancer

Restraint

- Stringent regulatory policies

Opportunity

- Rise in healthcare expenditure for cancer diagnosis and treatment

Market Players

Some of the key market players operating in the Europe colorectal cancer diagnostics market are

- F. Hoffmann-La Roche Ltd.

Scotts International, EU Vat number: PL 6772247784

- Thermo Fisher Scientific, Inc.
- QIAGEN
- Abbott
- Siemens Healthcare GmbH
- Merck KGAA
- Hologic, Inc.
- Agilent Technologies, Inc.
- Illumina, Inc.
- Myriad Genetics, Inc.
- Quest Diagnostics Incorporated.
- Bio-Rad Laboratories, Inc.
- Koninklijke Philips N.V.
- BD
- Time Medical Holding
- PlexBio
- Neusoft Corporation
- BioFire Diagnostics
- MinFound Medical Systems Co., Ltd
- Medonica Co. LTD
- CANON MEDICAL SYSTEMS CORPORATION

#### **Table of Contents:**

TABLE OF CONTENTS

- 1 INTRODUCTION 20
- 1.1 OBJECTIVES OF THE STUDY 20
- 1.2 MARKET DEFINITION 20
- 1.3 OVERVIEW OF THE EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET 20
- 1.4 LIMITATIONS 22
- 1.5 MARKETS COVERED 22
- 2 MARKET SEGMENTATION 25
- 2.1 MARKETS COVERED 25
- 2.2 GEOGRAPHICAL SCOPE 26
- 2.3 YEARS CONSIDERED FOR THE STUDY 27
- 2.4 CURRENCY AND PRICING 27
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 28
- 2.6 MULTIVARIATE MODELLING 31
- 2.7 PRODUCT TYPE LIFELINE CURVE 31
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 32
- 2.9 DBMR MARKET POSITION GRID 33
- 2.10 MARKET END USER COVERAGE GRID 34
- 2.11 VENDOR SHARE ANALYSIS 35
- 2.12 SECONDARY SOURCES 36
- 2.13 ASSUMPTIONS 36
- 3 EXECUTIVE SUMMARY 37
- 4 PREMIUM INSIGHTS 40
- 4.1 PORTER'S FIVE FORCES 42

Scotts International. EU Vat number: PL 6772247784

- 4.2 PESTEL ANALYSIS 43
- 5 INDUSTRY INSIGHTS: 44
- 6 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, REGULATIONS 45
- 6.1 REGULATORY SCENARIO IN THE GERMANY 45
- 6.2 REGULATORY SCENARIO IN FRANCE 45
- 6.3 REGULATORY SCENARIO IN RUSSIA 46
- 6.4 REGULATORY SCENARIO IN ITALY 46?
- 7 MARKET OVERVIEW 47
- 7.1 DRIVERS 49
- 7.1.1 GROWING PREVALENCE OF COLORECTAL CANCER 49
- 7.1.2 RISE IN THE NUMBER OF PATIENTS SUFFERING FROM DIVERTICULITIS AND ULCERATIVE COLITIS. 49
- 7.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 49
- 7.2 RESTRAINTS 50
- 7.2.1 STRINGENT REGULATORY POLICIES 50
- 7.2.2 HIGH COST FOR THE COLORECTAL CANCER TREATMENTS. 51
- 7.3 OPPORTUNITIES 51
- 7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 51
- 7.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 52
- 7.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 53
- 7.4 CHALLENGES 53
- 7.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 53
- 7.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 54
- 8 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 55
- 8.1 OVERVIEW 56
- 8.2 INSTRUMENTS 58
- 8.2.1 PATHOLOGY-BASED INSTRUMENTS 59
- 8.2.1.1 PCR INSTRUMENTS 60
- 8.2.1.2 SLIDE STAINING SYSTEMS 60
- 8.2.1.3 TISSUE PROCESSING SYSTEMS 60
- 8.2.1.4 CELL PROCESSORS 60
- 8.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS 60
- 8.2.2 IMAGING INSTRUMENTS 61
- 8.2.2.1 ULTRASOUND SYSTEMS 61
- 8.2.2.2 CT SYSTEMS 61
- 8.2.2.3 MRI SYSTEMS 61
- 8.2.2.4 OTHERS 61
- 8.2.3 BIOPSY INSTRUMENTS 61
- 8.2.4 OTHERS 62
- 8.3 CONSUMABLES & ACCESSORIES 62
- 8.3.1 KITS 63
- 8.3.1.1 PCR KITS 63
- 8.3.1.2 DNA POLYMERASE KITS 63
- 8.3.1.3 NUCLEIC ACID ISOLATION KITS 63
- 8.3.1.4 OTHERS 63?
- 8.3.2 REAGENTS 64
- 8.3.2.1 ASSAYS 64
- 8.3.2.2 BUFFERS 64

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.3.2.3 PRIMERS 64
- 8.3.2.4 OTHERS 64
- 8.3.3 OTHER CONSUMABLES 64
- 9 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE 65
- 9.1 OVERVIEW 66
- 9.2 STOOL EXAMINATION 68
- 9.3 BLOOD TEST 69
- 9.3.1 COMPLETE BLOOD COUNT (CBC) 70
- 9.3.2 TUMOR MARKER TEST 70
- 9.3.3 LIVER ENZYME BLOOD TEST 70
- 9.4 IMAGING TEST 70
- 9.4.1 COMPUTED TOMOGRAPHY (CT) SCAN 71
- 9.4.2 MRI 71
- 9.4.3 ULTRASOUND 71
- 9.4.4 POSITION EMISSION TOMOGRAPHY (PET) 71
- 9.4.5 OTHERS 71
- 9.5 TUMOR MARKERS 72
- 9.5.1 CARCINOEMBRYONIC ANTIGEN (CEA) 72
- 9.5.2 CA19-9 BIOMARKER TEST 72
- 9.5.3 CA 50 MARKER TEST 73
- 9.5.4 OTHERS 73
- 9.6 BIOPSY 73
- 9.7 OTHERS 73
- 10 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES 74
- **10.1 OVERVIEW 75**
- 10.2 STAGE III 77
- 10.3 STAGE IV 78
- 10.4 STAGE II 78
- 10.5 STAGE I 79
- 10.6 STAGE 0 79
- 11 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP 80
- 11.1 OVERVIEW 81
- 11.2 GERIATRIC 83
- 11.3 ADULTS 84
- 11.4 PEDIATRIC 84
- 12 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 85
- **12.1 OVERVIEW 86**
- 12.2 ADENOCARCINOMA 88
- 12.3 COLORECTAL LYMPHOMA 89
- 12.4 GASTROINTESTINAL STROMAL TUMORS 89
- 12.5 CARCINOID TUMORS 90
- 12.6 OTHERS 90
- 13 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER 91
- 13.1 OVERVIEW 92
- 13.2 HOSPITALS 95
- 13.3 DIAGNOSTIC CENTERS 95
- 13.4 CANCER RESEARCH CENTERS 95

- 13.5 AMBULATORY SURGICAL CENTERS 96
- 13.6 ACADEMIC INSTITUTES 96
- 13.7 OTHERS 96
- 14 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY COUNTRY 98
- 14.1 EUROPE 98
- 14.1.1 GERMANY 103
- 14.1.2 FRANCE 108
- 14.1.3 U.K. 113
- 14.1.4 ITALY 118
- 14.1.5 SPAIN 123
- 14.1.6 RUSSIA 128
- 14.1.7 TURKEY 133
- 14.1.8 NETHERLANDS 138
- 14.1.9 BELGIUM 143
- 14.1.10 SWITZERLAND 148
- 14.1.11 REST OF EUROPE 153
- 15 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 154
- 15.1 COMPANY SHARE ANALYSIS: EUROPE 154
- 16 SWOT ANALYSIS 155
- 17 COMPANY PROFILES 156
- 17.1 F. HOFFMANN- LA ROCHE LTD 156
- 17.1.1 COMPANY SNAPSHOT 156
- 17.1.2 REVENUE ANALYSIS 156
- 17.1.3 PRODUCT PORTFOLIO 157
- 17.1.4 RECENT DEVELOPMENT 157
- 17.2 KONINKLIJKE PHILIPS N.V. 158
- 17.2.1 COMPANY SNAPSHOT 158
- 17.2.2 REVENUE ANALYSIS 158
- 17.2.3 PRODUCT PORTFOLIO 159
- 17.2.4 RECENT DEVELOPMENT 159
- 17.3 THERMO FISHER SCIENTIFIC INC. 160
- 17.3.1 COMPANY SNAPSHOT 160
- 17.3.2 REVENUE ANALYSIS 160
- 17.3.3 PRODUCT PORTFOLIO 160
- 17.3.4 RECENT DEVELOPMENT 161
- 17.4 ILLUMINA, INC. 162
- 17.4.1 COMPANY SNAPSHOT 162
- 17.4.2 REVENUE ANALYSIS 162
- 17.4.3 PRODUCT PORTFOLIO 163
- 17.4.4 RECENT DEVELOPMENT 163
- 17.5 QUEST DIAGNOSTICS INCORPORATED 164
- 17.5.1 COMPANY SNAPSHOT 164
- 17.5.2 REVENUE ANALYSIS 164
- 17.5.3 PRODUCT PORTFOLIO 165
- 17.5.4 RECENT DEVELOPMENT 165
- 17.6 ABBOTT 166
- 17.6.1 COMPANY SNAPSHOT 166

- 17.6.2 REVENUE ANALYSIS 166
- 17.6.3 PRODUCT PORTFOLIO 167
- 17.6.4 RECENT DEVELOPMENT 167
- 17.7 AGILENT TECHNOLOGIES, INC. 168
- 17.7.1 COMPANY SNAPSHOT 168
- 17.7.2 REVENUE ANALYSIS 168
- 17.7.3 PRODUCT PORTFOLIO 169
- 17.7.4 RECENT DEVELOPMENT 169
- 17.8 BD 170
- 17.8.1 COMPANY SNAPSHOT 170
- 17.8.2 REVENUE ANALYSIS 170
- 17.8.3 PRODUCT PORTFOLIO 171
- 17.8.4 RECENT DEVELOPMENT 171
- 17.9 BIOFIRE DIAGNOSTICS 172
- 17.9.1 COMPANY SNAPSHOT 172
- 17.9.2 REVENUE ANALYSIS 172
- 17.9.3 PRODUCT PORTFOLIO 173
- 17.9.4 RECENT DEVELOPMENT 173
- 17.10 BIO-RAD LABORATORIES, INC. 174
- 17.10.1 COMPANY SNAPSHOT 174
- 17.10.2 REVENUE ANALYSIS 174
- 17.10.3 PRODUCT PORTFOLIO 175
- 17.10.4 RECENT DEVELOPMENT 175
- 17.11 CANON MEDICAL SYSTEMS CORPORATION. 176
- 17.11.1 COMPANY SNAPSHOT 176
- 17.11.2 REVENUE ANALYSIS 176
- 17.11.3 PRODUCT PORTFOLIO 177
- 17.11.4 RECENT DEVELOPMENT 177
- 17.12 FONAR CORP. 178
- 17.12.1 COMPANY SNAPSHOT 178
- 17.12.2 REVENUE ANALYSIS 178
- 17.12.3 PRODUCT PORTFOLIO 179
- 17.12.4 RECENT DEVELOPMENT 179
- 17.13 FUJIFILM CORPORATION 180
- 17.13.1 COMPANY SNAPSHOT 180
- 17.13.2 REVENUE ANALYSIS 180
- 17.13.3 PRODUCT PORTFOLIO 181
- 17.13.4 RECENT DEVELOPMENT 181
- 17.14 GE HEALTHCARE. 182
- 17.14.1 COMPANY SNAPSHOT 182
- 17.14.2 REVENUE ANALYSIS 182
- 17.14.3 PRODUCT PORTFOLIO 183
- 17.14.4 RECENT DEVELOPMENT 183
- 17.15 HOLOGIC, INC. 184
- 17.15.1 COMPANY SNAPSHOT 184
- 17.15.2 REVENUE ANALYSIS 184
- 17.15.3 PRODUCT PORTFOLIO 184

17.15.4 RECENT DEVELOPMENT 185

17.16 MEDONICA CO. LTD 186

17.16.1 COMPANY SNAPSHOT 186

17.16.2 PRODUCT PORTFOLIO 186

17.16.3 RECENT DEVELOPMENT 186

17.17 MERCK KGAA 187

17.17.1 COMPANY SNAPSHOT 187

17.17.2 REVENUE ANALYSIS 187

17.17.3 PRODUCT PORTFOLIO 187

17.17.4 RECENT DEVELOPMENT 188



Print this form

To place an Order with Scotts International:

 $\hfill \Box$  - Complete the relevant blank fields and sign

# **Europe Colorectal Cancer Diagnostics Market - Industry Trends and Forecast to 2030**

Market Report | 2023-09-01 | 205 pages | Data Bridge Market Research

ORDER FORM:				
elect license	License			Price
	Single User License			\$3500.00
	Corporate Users License			\$4200.00
				tal
llease sircle the relev	ant licence ention. For any questions pla	oaso contact cunnort@	occatta international com or 0049 60	2 204 246
	ant license option. For any questions plo t 23% for Polish based companies, indiv			
VAT WIII DE dadea e	2270 for Folish based companies, man	riduais and Lo basea e	companies who are unable to provide	. a valla LO va
:mail*		Phone*		
irst Name*		Last Name*		
ob title*				
Company Name* [		EU Vat / Tax ID / NIP number*		
-		City*		
\ddress*				
L		Country*		
L		Country* Date	2025-05-10	
L		Date	2025-05-10	
Address* Zip Code*		-	2025-05-10	
L		Date	2025-05-10	

Scotts International. EU Vat number: PL 6772247784